From Inside Attack to Iowa Expansion: CSG’s Split Screen of Operations and Share Price
Published on 07/20/2026 at 08:31 | Redaktion boerse-global.de
The Czechoslovak Group (CSG) is charging ahead with one of the largest single-site artillery shell capacity expansions in the United States, even as its stock remains mired near half-year lows after a bruising short-seller assault. The defense contractor’s American subsidiary, MSM North America, has broken ground on the Future Artillery Complex (FAC) inside the Iowa Army Ammunition Plant (IAAAP). The facility will replace a production line that is more than 50 years old and is designed to churn out 36,000 rounds of 155mm ammunition per month once fully operational by 2029.
The project carries a 40-month construction timeline, with full commissioning pegged for 48 months. It slots into a broader ramp-up already underway at the Iowa site: output stood at 30,000 shells per month as of March 2026, and the target is 78,000 units per month by the end of 2027. With the FAC online, total plant capacity could potentially reach 114,000 rounds monthly — nearly quadrupling current production in just a few years. The contract, signed in 2025, is valued at up to $632 million.
CSG is also scaling its artillery technology internationally through a licensing deal in Ukraine, where production of 100,000 long-range shells annually is planned. Domestically, the group recently established a new American subsidiary, CSG Land Systems North America, based in Michigan. This entity consolidates the U.S. operations of Excalibur Army, Tatra Defence and Tatra Trucks, covering armored vehicles, artillery systems and military logistics trucks.
Should investors sell immediately? Or is it worth buying CSG?
These operational strides contrast sharply with the stock’s recent performance. Shares closed Friday at €14.39, a 4.44% gain from the prior session, but that rally does little to repair the damage inflicted over the past few months. The stock hit a 52-week low of €12.20 just three weeks ago, and even after the bounce it remains roughly 60% below the January record high of €36.05 — a peak reached shortly after the company’s widely celebrated Amsterdam listing.
The trigger for the sell-off was a May report from U.S. short seller Hunterbrook, which alleged that CSG largely resells munitions made by third parties rather than manufacturing them in-house, and that its IPO prospectus omitted key information. CSG pushed back forcefully, stating it produces ammunition at multiple sites across several countries with an output of around 630,000 rounds. Hunterbrook published a follow-up in mid-May; CSG dismissed it as a selective reading of publicly available data.
The confrontation has left a lasting imprint on the stock’s trading pattern. The annualized volatility over the past 30 sessions stands above 52%, and the relative strength index at 50.7 signals a market split on whether the worst is over. The stock continues to trade below its 50-day moving average of €15.21, suggesting no clear trend reversal is yet in place.
For CSG, the multi-year timeline of the Iowa plant provides a stable, long-term order backlog within one of NATO’s key munitions facilities. Investors will likely watch for further contract awards tied to the broader Western artillery build-up, as well as the next quarterly results due in August, to see whether production capacity and order visibility can eventually drag the share price back from the brink.
Ad
CSG Stock: New Analysis - 20 July
Fresh CSG information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
